Resistance to Nevirapine of HIV-1 reverse transcriptase mutants: Loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions

Journal of Molecular Biology

Volumn 274, Issue 5, 1997, Pages 738-747

  Maga, Giovanni ^a   Amacker, Mario ^b   Ruel, Nancy ^b   Hübscher, Ulrich ^b   Spadari, Silvio ^a  

^a Inst of Biochem and Evol G   (Italy)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Drug resistance; HIV 1; Non nucleoside inhibitors; Reverse transcriptase

Indexed keywords

ENZYME INHIBITOR; MUTANT PROTEIN; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; VIRUS ENZYME;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; STEREOCHEMISTRY; THERMODYNAMICS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0031578901     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1997.1427     Document Type: Article

References (37)

1. Balzarini J., DeClercq E. Analysis of inhibition of retroviral reverse transcriptase. Methods Enzymol. 275:1996;472-503.
2. Balzarini J., Karlsson A., Perez-Perez M. J., Vrang L., Walbers J., Zhang H., Oberg B., Vandamme A. M., Camarasa M. J., De Clercq E. HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology. 192:1993;246-253.
3. Balzarini J., Pelemans H., Karlsson A., DeClercq E., Kleim J.-P. Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors. Proc. Natl Acad. Sci. USA. 93:1996;13152-13157.
4. Boyer P. L., Currens M. J., McMahon J. B., Boyd M. R., Hughes S. H. Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 67:1993;2412-2420.
5. Boyer P. L., Ding J., Arnold E., Hughes S. H. Drug resistance of human immunodeficiency virus type 1 reverse transcriptase: subunit specificity of mutations that confere resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 38:1994a;1909-1914.
6. Boyer P. L., Ferris A. L., Clark P., Whitmer J., Frank P., Tantillo C., Arnold E., Hughes S. H. Mutational analysis of the fingers and palm subdomains of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase. J. Mol. Biol. 243:1994b;472-483.
7. Das K., Ding J., Hsiou Y., Clark A. D. Jr, Moereels H., Koymans L., Andries K., Pauwuels R., Janssen P. A. J., Boyer P. L., Clark P., Smith R. H. Jr, Kroeger Smith M. B., Michejda C. J., Hughes S. H., Arnold E. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug resistant mutant. J. Mol. Biol. 264:1996;1085-1100.
8. DeClercq E. HIV-1-specific reverse transcriptase inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase. Medicinal Res. Rev. 13:1993;229-258.
9. Ding J., Das K., Moereels H., Koymans L., Andries K., Janssen P. A. J., Hughes S. H., Arnold E. Structure of HIV-1 RT/TIBO R86183 reveals similarity in the binding of diverse non-nucleoside inhibitors. Nature Struct. Biol. 2:1995a;407-415.
10. Ding J., Das K., Tantillo C., Zhang W., Clark A. D. Jr, Jessen S., Lu X., Hsiou Y., Jacobo-Molina A., Andries K., Pauwels R., Moereels H., Koymans L., Janssen P. A., Smith R., Koepke M. K., Michejda C., Hughes S. H., Arnold E. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R95845 at 2. 8 Å resolution. Structure. 3:1995b;365-379.
11. Esnouf R., Ren J., Ross C., Jones Y., Stammers D., Stuart D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nature Struct. Biol. 2:1995;303-308.
12. Esnouf R., Stuart D. I., DeClercq E., Schwartz E., Balzarini J. Models which explain the inhibition of reverse transcriptase by HIV-1 specific (thio)carboxanilide derivatives. Biochem. Biophys. Res. Comm. 234:1997;458-464.
13. Grob P. M., Wu J. C., Choen K. A., Ingraham R. H., Shih C. K., Hargrave K. D., McTague T. L., Merluzzi V. J. Non-nucleoside inhibitors of HIV-1 reverse transcriptase: Nevirapine as a prototype drug. AIDS Res. Hum. Retroviruses. 8:1992;145-152.
14. Hopkins A. L., Ren J., Esnouf R. M., Willcox B. E., Yvonne Jones E., Ross C., Miyasaka T., Walker R. T., Tanaka H., Stammers D. K., Stuart D. I. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J. Med. Chem. 39:1996;1589-1600.
15. Hottiger M., Hübscher U. Human immunodeficiency virus type 1 reverse transcriptase. Biol. Chem. Hoppe-Seyler. 377:1996;97-120.
16. Hsieh J.-C., Zinnen S., Modrich P. Kinetic mechanism of the DNA-dependent DNA polymerase activity of human immunodeficiency virus reverse transcriptase. J. Biol. Chem. 268:1993;24607-24613.
17. Hsiou Y., Ding J., Das K., Clark A. D. Jr, Hughes S. H., Arnold E. Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure. 4:1996;853-860.
18. Hübscher U., Spadari S. DNA replication and chemotherapy. Physiol. Rev. 74:1994;259-304.
19. Jacobo-Molina A., Ding J., Nanni R. G., Clark A. D. Jr, Lu X., Tantillo C., Williams R. L., Kamer G., Ferris A. L., Clark P., Hizi A., Hughes S. H., Arnold E. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc. Natl Acad. Sci. USA. 90:1993;6320-6324.
20. Kati W. M., Johnson K. A., Jerva L. F., Anderson K. S. Mechanism and fidelity of HIV reverse transcriptase. J. Biol. Chem. 267:1992;25988-25997.
21. Kohlstaedt L. A., Wang J., Friedman J. M., Rice P. A., Steizt T. A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 256:1992;1783-1790.
22. Kroeger Smith M. B., Rouzer C. A., Taneyhill L. A., Smith N. A., Hughes S. H., Boyer P. L., Janssen P. A. J., Moereels H., Koymans L., Arnold E., Ding J., Das K., Zhang W., Michejda C., Smith R. H. Jr. Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity. Protein Sci. 4:1995;2203-2222.
23. Larder B. A. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J. Gen. Virol. 75:1994;951-957.
24. Mellors J. W., G. E. D., Im G. J., Tramontano E., Winkler S. R., Cheng Y. C. In vitro. Mol. Pharmacol. 41:1992;446-451.
25. Merluzzi V. J., Hargrave K. D., Labadia M., Grozinger K., Skoog M., Wu J. C., Shih C. K., Eckner K., Hattox S., Adams J. et al. Inhibition of HIV-1 replication by a non-nucleoside reverse transcriptase inhibitor. Science. 250:1990;1411-1413.
26. Oxford J. S., Al-Jabri A. A., Stein C. A., Levantis P. Analysis of resistance mutants of viral polymerases. Methods Enzymol. 275:1996;555-601.
27. Ren J., Esnouf R., Garman E., Somers D., Ross C., Kirby I., Keeling J., Darby G., Jones Y., Stuart D., Stammers D. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nature Struct. Biol. 2:1995a;293-302.
28. Ren J., Esnouf R., Hopkins A., Ross C., Jones Y., Stammers D., Stuart D. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure. 3:1995b;915-926.
29. Richman D., Rosenthal A. S., Skoog M., Eckner R. J., Chou T. C., Sabo J. P., Merluzzi V. J. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob. Agents Chemother. 35:1991a;305-308.
30. Richman D., Shih C. K., Lowy I., Prodanovich P., Goff S., Griffin J. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl Acad. Sci. USA. 88:1991b;11241-11245.
31. Richman D. D., Havlir D., Corbeil J., Looney D., Ignacio C., Spector S. A., Sullivan J., Cheeseman S., Barringer K., Pauletti D., Shih C.-K., Myers M., Griffin J. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1994;1660-1666.
32. Rittinger K., Divita G., Goody R. Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. Proc. Natl Acad. Sci. USA. 92:1995;8046-8049.
33. Rodgers D. W., Gamblin S. J., Harris B. A., Ray S., Culp J. S., Hellmig B., Woolf D. J., Debouck C., Harrison S. C. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA. 92:1995;8046-8049.
34. Smerdon S. J., Jager J., Wang J., Kohlstaedt L. A., Chirino A. J., Friedman J. M., Rice P. A., Steizt T. A. Structure of the binding site for non-nucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA. 91:1994;3911-3915.
35. Spence R. A., Anderson K. S., Johnson K. A. HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors. Biochemistry. 35:1996;1054-1063.
36. Spence R. A., Kati W. M., Anderson K. S., Johnson K. A. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science. 267:1995;988-993.
37. Tantillo C., Ding J., Jacobo-Molina A., Nanni R. G., Boyer P. L., Hughes S. H., Pauwels R., Andries K., Janssen P. A., Arnold E. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. J. Mol. Biol. 243:1994;369-387.